Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A2 | P19784 | 5/20 | 1.00 |
| ▸ | CSNK2B | P67870 | 5/20 | 1.00 |
| ▸ | CSNK2A1 | P68400 | 5/20 | 1.00 |
| ▸ | PIM1 | P11309 | 15/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1760711 | 0.90 | CSNK2A2 (0.82) | CSNK2A2CSNK2BCSNK2A1PIM1 | |
| SCHEMBL1815017 | 0.80 | PIM1 (1.00) | CSNK2A2CSNK2BCSNK2A1PIM1 | |
| SCHEMBL1819537 | 0.80 | CSNK2A2 (0.83) | CSNK2A2CSNK2BCSNK2A1PIM1 | |
| SCHEMBL1814527 | 0.79 | PIM1 (1.00) | CSNK2A2CSNK2BCSNK2A1PIM1 | |
| SCHEMBL1815696 | 0.79 | PIM1 (0.65) | CSNK2A2CSNK2BCSNK2A1PIM1 | |
| SCHEMBL1816958 | 0.76 | PIM1 (1.00) | CSNK2A2CSNK2BCSNK2A1PIM1 | |
| SCHEMBL12648161 | 0.76 | PIM1 (0.66) | CSNK2A2CSNK2BCSNK2A1PIM1 | |
| SCHEMBL10325090 | 0.76 | PIM1 (0.66) | CSNK2A2CSNK2BCSNK2A1PIM1 | |
| SCHEMBL1759472 | 0.76 | PIM1 (0.66) | CSNK2A2CSNK2BCSNK2A1PIM1 | |
| SCHEMBL1760267 | 0.76 | CSNK2A2 (1.00) | CSNK2A2CSNK2BCSNK2A1PIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110230481-A2 | DERIVATIVES OF TETRABROMOBENZIMIDAZOLE, A PROCESS FOR THE PREPARATION THEREOF, A PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, A METHOD OF USING THE SAME, A METHOD FOR MODULATING OR REGULATING SERINE/THREONINE KINASES, AND SERINE/THREONINE KINASES MODULATING AGENT | SELVITA S.A. (PL) | 2011-09-22 | — | — | US | claimed |
| EP-2366695-A1 | A compound, a process for its preparation, a pharmaceutical composition, use of a compound, a method for modulating or regulating serine/threonine kinases and a serine/threonine kinases modulating agent | SELVITA S.A. (PL) | 2011-09-21 | — | — | EP | claimed |
| US-20110112091-A1 | DERIVATIVES OF TETRABROMOBENZIMIDAZOLE, A PROCESS FOR THE PREPARATION THEREOF, A PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, A METHOF OF USING THE SAME, A METHOD FOR MODULATING OR REGULATING SERINE/THREONINE KINASES, AND SERINE/THREONINE KINASES MODULATING AGENT | SELVITA SP. Z O.O. (PL) | 2011-05-12 | — | — | US | claimed |
| US-20090239921-A1 | METHODS FOR TREATING NEOPLASMS WITH DERIVATIVES OF 4,5,6,7-TETRABROMOBENZIMIDAZOLE | SELVITA SP. Z.O.O. (PL) | 2009-09-24 | — | — | US | claimed |
| US-7528259-B2 | Derivatives of 4,5,6,7-tetrabromobenzimidazole and method of their preparation | SELVITA SP. Z O. O. (PL) | 2009-05-05 | — | — | US | claimed |
| US-20070213385-A1 | NEW DERIVATIVES OF 4,5,6,7-TETRABROMOBENZIMIDAZOLE AND METHOD OF THEIR PREPARATION | SELVITA S.A. (PL) | 2007-09-13 | — | — | US | claimed |
| US-20200206188-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO | BROWN DENNIS M (US) | 2020-07-02 | — | — | US | disclosed |
| US-10383847-B2 | Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo | BROWN DENNIS M (US) | 2019-08-20 | — | — | US | disclosed |
| US-20160243077-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO | BROWN DENNIS M (US) | 2016-08-25 | — | — | US | disclosed |
| US-8604217-B2 | Compound, a process for its preparation, a pharmaceutical composition, use of a compound, a method for modulating or regulating serine/threonine kinases and a serine/threonine kinases modulating agent | SELVITA S.A. (PL) | 2013-12-10 | — | — | US | disclosed |
| US-20120184535-A1 | COMPOUND, A PROCESS FOR ITS PREPARATION, A PHARMACEUTICAL COMPOSITION, USE OF A COMPOUND, A METHOD FOR MODULATING OR REGULATING SERINE/THREONINE KINASES AND A SERINE/THREONINE KINASES MODULATING AGENT | SELVITA S.A. (PL) | 2012-07-19 | — | — | US | disclosed |
| US-20110230481-A2 | DERIVATIVES OF TETRABROMOBENZIMIDAZOLE, A PROCESS FOR THE PREPARATION THEREOF, A PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, A METHOD OF USING THE SAME, A METHOD FOR MODULATING OR REGULATING SERINE/THREONINE KINASES, AND SERINE/THREONINE KINASES MODULATING AGENT | SELVITA S.A. (PL) | 2011-09-22 | — | — | US | disclosed |
| EP-2366695-A1 | A compound, a process for its preparation, a pharmaceutical composition, use of a compound, a method for modulating or regulating serine/threonine kinases and a serine/threonine kinases modulating agent | SELVITA S.A. (PL) | 2011-09-21 | — | — | EP | disclosed |
| US-20110112091-A1 | DERIVATIVES OF TETRABROMOBENZIMIDAZOLE, A PROCESS FOR THE PREPARATION THEREOF, A PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, A METHOF OF USING THE SAME, A METHOD FOR MODULATING OR REGULATING SERINE/THREONINE KINASES, AND SERINE/THREONINE KINASES MODULATING AGENT | SELVITA SP. Z O.O. (PL) | 2011-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10383847-B2 | Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo | NEK9, NEK7, NEK3 | CSNK2A2 161/4885CSNK2B 190/4885CSNK2A1 132/4885 |
| US-20110112091-A1 | DERIVATIVES OF TETRABROMOBENZIMIDAZOLE, A PROCESS FOR THE PREPARATION THEREOF, A PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, A METHOF OF USING THE SAME, A METHOD FOR MODULATING OR REGULATING SERINE/THREONINE KINASES, AND SERINE/THREONINE KINASES MODULATING AGENT | PIM1, PIM2, PIM3 | CSNK2A2 186/4885CSNK2B 185/4885CSNK2A1 152/4885 |
| US-20200206188-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO | NEK9, NEK7, NEK3 | CSNK2A2 161/4885CSNK2B 190/4885CSNK2A1 132/4885 |
| US-20120184535-A1 | COMPOUND, A PROCESS FOR ITS PREPARATION, A PHARMACEUTICAL COMPOSITION, USE OF A COMPOUND, A METHOD FOR MODULATING OR REGULATING SERINE/THREONINE KINASES AND A SERINE/THREONINE KINASES MODULATING AGENT | ITK, HASPIN, HCK | CSNK2A2 418/4885CSNK2B 321/4885CSNK2A1 349/4885 |
| US-20070213385-A1 | NEW DERIVATIVES OF 4,5,6,7-TETRABROMOBENZIMIDAZOLE AND METHOD OF THEIR PREPARATION | CYP3A4, IL4I1, CYP4B1 | CSNK2A2 1023/4885CSNK2B 840/4885CSNK2A1 1059/4885 |
| US-20090239921-A1 | METHODS FOR TREATING NEOPLASMS WITH DERIVATIVES OF 4,5,6,7-TETRABROMOBENZIMIDAZOLE | CSNK2A2, CSNK2A1, CSNK2B | CSNK2A2 1/4885CSNK2B 3/4885CSNK2A1 2/4885 |
| US-20110230481-A2 | DERIVATIVES OF TETRABROMOBENZIMIDAZOLE, A PROCESS FOR THE PREPARATION THEREOF, A PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, A METHOD OF USING THE SAME, A METHOD FOR MODULATING OR REGULATING SERINE/THREONINE KINASES, AND SERINE/THREONINE KINASES MODULATING AGENT | PIM1, PIM2, PIM3 | CSNK2A2 58/4885CSNK2B 40/4885CSNK2A1 46/4885 |
| US-20160243077-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO | NEK9, NEK7, NEK3 | CSNK2A2 161/4885CSNK2B 190/4885CSNK2A1 132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.